Home > For Consumers > Length of time needed for antibiotic...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries.

Length of time needed for antibiotic treatment given directly into the blood stream to clear acute chest infections in people with cystic fibrosis

This version published: 2013; Review content assessed as up-to-date: March 27, 2013.

Plain language summary

Chest infections in people with cystic fibrosis are treated aggressively to prevent further damage to the lungs. This has led to better survival rates for people with cystic fibrosis in recent years. There are no clear guidelines on how long chest infections should be treated with intravenous antibiotics (antibiotics administered directly into the blood stream). Different centres tend to use different treatment regimens. Most centres use 10 or 14 days, extending this to 21 days if there is no improvement in a patient's symptoms. We could not find any studies comparing 10 days treatment with 14 days or longer treatment. A shorter duration of treatment may be better as these courses of treatment are easier for people to complete. They are also less expensive and cause fewer drug reactions than longer treatments. However, it is not clear if shorter treatment is enough to treat infections adequately. It is also not clear whether shorter treatment results in early recurrence or increased frequency of chest infections. Further research is needed to find the optimum duration for treating chest infections.


Background: Respiratory disease is the major cause of mortality and morbidity in cystic fibrosis (CF). Life expectancy of people with CF has increased dramatically in the last 40 years. One of the major reasons for this increase is the mounting use of antibiotics to treat chest exacerbations caused by bacterial infections. The optimal duration of intravenous antibiotic therapy is not clearly defined. Individuals usually receive intravenous antibiotics for 14 days, but treatment may range from 10 to 21 days. A shorter duration of antibiotic treatment risks inadequate clearance of infection which could lead to further lung damage. Prolonged courses of intravenous antibiotics are expensive and inconvenient and the incidence of allergic reactions to antibiotics also increases with prolonged courses. The use of aminoglycosides requires frequent monitoring to avoid some of their side effects. However, some organisms which infect people with CF are known to be multi‐resistant to antibiotics, and may require a longer course of treatment.

Objectives: To assess the optimal duration of intravenous antibiotic therapy for treating chest exacerbations in people with cystic fibrosis.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals, abstract books and conference proceedings.

Most recent search of the Group's Cystic Fibrosis Trials Register: 15 November 2012.

Selection criteria: Randomised and quasi‐randomised controlled trials comparing different durations of intravenous antibiotic courses for acute respiratory exacerbations in people with CF, either with the same drugs at the same dosage, the same drugs at a different dosage or frequency or different antibiotics altogether, including studies with additional therapeutic agents.

Data collection and analysis: No eligible trials were identified.

Main results: No eligible trials were identified.

Authors' conclusions: There are no clear guidelines on the optimum duration of intravenous antibiotic treatment. Duration of treatment is currently based on unit policies and response to treatment. Shorter duration of treatment should improve quality of life and compliance; result in a reduced incidence of drug reactions; and be less costly. However, this may not be sufficient to clear a chest infection and may result in an early recurrence of an exacerbation. This systematic review identifies the need for a multicentre, randomised controlled trial comparing different durations of intravenous antibiotic treatment as it has important clinical and financial implications.

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group.

Publication status: New search for studies and content updated (no change to conclusions).

Citation: Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD006682. DOI: 10.1002/14651858.CD006682.pub4. Link to Cochrane Library. [PubMed: 23728662]

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...